Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation

Paul M. Cinciripini, David W. Wetter, Cho Lam, Carl De Moor, Lynn Cinciripini, Walter Baile, Janice Y. Tsoh, Cheryl Anderson, John D. Minna

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.

Original languageEnglish (US)
Pages (from-to)282-292
Number of pages11
JournalExperimental and Clinical Psychopharmacology
Volume13
Issue number4
DOIs
StatePublished - Nov 2005

Fingerprint

Smoking Cessation
Nicotine
Counseling
Therapeutics
Tobacco Products
Venlafaxine Hydrochloride
Placebos
Recurrence

ASJC Scopus subject areas

  • Pharmacology
  • Experimental and Cognitive Psychology

Cite this

Cinciripini, P. M., Wetter, D. W., Lam, C., De Moor, C., Cinciripini, L., Baile, W., ... Minna, J. D. (2005). Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Experimental and Clinical Psychopharmacology, 13(4), 282-292. https://doi.org/10.1037/1064-1297.13.4.282

Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. / Cinciripini, Paul M.; Wetter, David W.; Lam, Cho; De Moor, Carl; Cinciripini, Lynn; Baile, Walter; Tsoh, Janice Y.; Anderson, Cheryl; Minna, John D.

In: Experimental and Clinical Psychopharmacology, Vol. 13, No. 4, 11.2005, p. 282-292.

Research output: Contribution to journalArticle

Cinciripini, PM, Wetter, DW, Lam, C, De Moor, C, Cinciripini, L, Baile, W, Tsoh, JY, Anderson, C & Minna, JD 2005, 'Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation', Experimental and Clinical Psychopharmacology, vol. 13, no. 4, pp. 282-292. https://doi.org/10.1037/1064-1297.13.4.282
Cinciripini, Paul M. ; Wetter, David W. ; Lam, Cho ; De Moor, Carl ; Cinciripini, Lynn ; Baile, Walter ; Tsoh, Janice Y. ; Anderson, Cheryl ; Minna, John D. / Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. In: Experimental and Clinical Psychopharmacology. 2005 ; Vol. 13, No. 4. pp. 282-292.
@article{def08fa353eb4789aee0e31e27f1267a,
title = "Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation",
abstract = "In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.",
author = "Cinciripini, {Paul M.} and Wetter, {David W.} and Cho Lam and {De Moor}, Carl and Lynn Cinciripini and Walter Baile and Tsoh, {Janice Y.} and Cheryl Anderson and Minna, {John D.}",
year = "2005",
month = "11",
doi = "10.1037/1064-1297.13.4.282",
language = "English (US)",
volume = "13",
pages = "282--292",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "4",

}

TY - JOUR

T1 - Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation

AU - Cinciripini, Paul M.

AU - Wetter, David W.

AU - Lam, Cho

AU - De Moor, Carl

AU - Cinciripini, Lynn

AU - Baile, Walter

AU - Tsoh, Janice Y.

AU - Anderson, Cheryl

AU - Minna, John D.

PY - 2005/11

Y1 - 2005/11

N2 - In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.

AB - In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.

UR - http://www.scopus.com/inward/record.url?scp=29444460233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29444460233&partnerID=8YFLogxK

U2 - 10.1037/1064-1297.13.4.282

DO - 10.1037/1064-1297.13.4.282

M3 - Article

C2 - 16366758

AN - SCOPUS:29444460233

VL - 13

SP - 282

EP - 292

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 4

ER -